Status:
RECRUITING
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Lead Sponsor:
Changhai Hospital
Collaborating Sponsors:
Ningbo University Affiliated People's Hospital
Jiaxing University Affiliated Second Hospital
Conditions:
Pancreatic Cancer
Intraductal Papillary Mucinous Neoplasm
Eligibility:
All Genders
50+ years
Brief Summary
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at adv...
Detailed Description
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive cancer with a dismal 5-year survival rate of just 13%. The key to improving outcomes lies in early detection, as patients diagnosed a...
Eligibility Criteria
Inclusion Criteria:
- Age 50 years and above.
- Voluntary signing of informed consent.
- Completion of LDCT examination.
Exclusion Criteria:
- Previous history of pancreatic cancer.
- Abdominal inflammation or diagnosis of acute pancreatitis within 6 months.
- Poor image quality due to ascites, pancreatic trauma, thoracic/abdominal surgery, radiotherapy or chemotherapy.
- Research subjects unable to complete follow-up due to physical or other reasons.
Key Trial Info
Start Date :
August 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2032
Estimated Enrollment :
400000 Patients enrolled
Trial Details
Trial ID
NCT07117045
Start Date
August 15 2025
End Date
December 30 2032
Last Update
August 12 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Meinian Onehealth Healthcare Holdings Co., Ltd
Shanghai, Shanghai Municipality, China, 200072
2
Ruici Medical Examination Institution
Shanghai, Shanghai Municipality, China, 200126
3
Changhai Hospital
Shanghai, Shanghai Municipality, China, 200433
4
Jiaxing University Affiliated Second Hospital
Jiaxing, Zhejiang, China, 314000